Home›Irbesartan And Hydrochlorothiazide›Irbesartan And Hydrochlorothiazide + Aliskiren

Does Irbesartan And Hydrochlorothiazide Interact with Aliskiren?

CDI records a contraindicated classification for Irbesartan And Hydrochlorothiazide and Aliskiren. The stored summary is: Do not coadminister aliskiren with irbesartan and hydrochlorothiazide in patients with diabetes. Avoid in patients with renal impairment (GFR <60 mL/min). The mechanism involves dual ras blockade. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Contraindicated
Irbesartan And Hydrochlorothiazide Class
Angiotensin 2 Receptor Blocker
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Dual RAS blockade

What To Tell Your Doctor or Pharmacist

If you are taking Irbesartan And Hydrochlorothiazide and your doctor is considering prescribing Aliskiren (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Irbesartan And Hydrochlorothiazide(Avalide)+💊 Aliskiren(Tekturna HCT)

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
CDI classifies this record as contraindicated. Confirm the applicable product labeling with your prescriber or pharmacist.
Severity scale
MinorContra
On record
Yes
Drug A class
Angiotensin 2 Receptor Blocker
Drug B class
—
Source
NLP:irbesartan and hydrochlorothiazide

What this means in plain English

Do not coadminister aliskiren with irbesartan and hydrochlorothiazide in patients with diabetes. Avoid in patients with renal impairment (GFR <60 mL/min).

About Irbesartan And Hydrochlorothiazide and Aliskiren

Irbesartan And Hydrochlorothiazide is an Angiotensin 2 Receptor Blocker. You may recognize them by the brand names Avalide and Tekturna HCT. Both Irbesartan And Hydrochlorothiazide and Aliskiren carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:irbesartan and hydrochlorothiazide

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Irbesartan And Hydrochlorothiazide and Aliskiren against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations